Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.

Journal: AIDS care

Volume: 36

Issue: 1

Year of Publication: 2024

Affiliated Institutions:  Women's Global Health Imperative, RTI International, Berkeley, CA, USA. FHI , Durham, NC, USA. Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda. Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. South African Medical Research Council, Durban, South Africa. University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Department of Biostatistics, University of Washington, Seattle, WA, USA. College of Medicine-John Hopkins University Research Project, Blantyre, Malawi. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Mental Health, and Eunice Shriver Kennedy, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. University of California San Francisco, San Francisco, CA, USA.

Abstract summary 

We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase III trial in Malawi, South Africa, Uganda, and Zimbabwe, 2012-2015;  = 2629). Transactional sex was defined as receipt of money, goods, gifts, drugs, or shelter in exchange for sex in the past year. Dimensions of acceptability included: ease of use and physical sensation in situ, impacts on sex, partner's opinion, and likelihood of future use. We used Poisson regression models with robust standard errors to compare risk of acceptability challenges by baseline history of transactional sex. At product discontinuation, women exchanging sex found the ring comfortable (90%), easy to insert (92%) and nearly all (96%) were likely to use the ring in the future. Women who had exchanged sex were more likely to report feeling the ring during sex (ARR 1.43, 95% CI: 1.09, 1.89;  = 0.01) and slightly more likely to mind wearing the ring during menses (ARR 1.22, 95% CI: 1.01, 1,46;  = 0.04) and during sex (ARR 1.22, 95% CI: 1.02, 1.45;  = 0.03). Messaging and counseling should include enhanced support for use during sex and menses to support optimal use.

Authors & Co-authors:  Browne Erica N EN Torjesen Kristine K Mirembe Brenda Gati BG Palanee-Phillips Thesla T Jeenarain Nitesha N Chitukuta Miria M Stoner Marie C D MCD Mansoor Leila E LE Reddy Krishnaveni K Tauya Thelma T TT Naidoo Logashvari L Siva Samantha S Richardson Barbra B Dadabhai Sufia S Seyama Linly L Soto-Torres Lydia L van der Straten Ariane A

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, … Team, M.-A. S. (2016). Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine, 375(22), 2121–2132. 10.1056/NEJMoa1506110
Authors :  18
Identifiers
Doi : 10.1080/09540121.2023.2198187
SSN : 1360-0451
Study Population
Women,Female
Mesh Terms
Female
Other Terms
HIV prevention;acceptability;sub-saharan Africa;transactional sex;vaginal ring;women
Study Design
Cross Sectional Study
Study Approach
Country of Study
Uganda
Publication Country
England